This page shows the latest Amylin news and features for those working in and with pharma, biotech and healthcare.
This was then expanded in 2012 when the alliance acquired Amylin, gaining the rights to a portfolio of products for type 2 diabetes, including the long-acting exenatide franchise (Byetta and
This was then expanded in 2012 when the alliance acquired Amylin, gaining the rights to a portfolio of products for type 2 diabetes, including the exenatide franchise (Byetta and Bydureon).
However, Lilly and Amylin mutually agreed to end their diabetes alliance in 2011, passing full control of the franchise to Amylin. ... The diabetes alliance of Bristol-Myers Squibb (BMS) and AstraZeneca then took control of the franchise in 2012 when BMS
BMS acquired rights to metreleptin when it bought Amylin in 2012. .
AZ will also have a commanding position in the latter category following the alliance's $7bn acquisition of Amylin in 2012.
Analysts at Panmure Gordon said the deal seemed "sensible", particularly in light of the fact that AZ paid $3.5bn for its 50 per cent share in Amylin alongside BMS last ... year. AZ now has full control of three Amylin-developed products, namely the
More from news
Approximately 2 fully matching, plus 34 partially matching documents found.
This was then expanded in 2012 when the alliance acquired Amylin, gaining the rights to a portfolio of products for type 2 diabetes, including the exenatide franchise (Byetta and Bydureon).
Campaign:Diabetes Close to the Heart. Timescale:January, 2010 to November, 2010. Chandler Chicco Agency, with Amylin Pharmaceuticals, Inc. ... Extending education beyond the live performance, CCA worked with Amylin to develop filmed adaptations of the
Additionally, the Alliance has grown into a multi-funder initiative and has received funding from Amylin Pharmaceuticals and Allergan.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Bruce has also held position at Amylin Pharmaceuticals, where he was in charge of Bydureon's phase III studies and safety analysis, a once weekly GLP-1 injectable formulation. ... Daly's experience in the diabetes field also includes several years at
Bradbury is an experienced figure in the life science industry, serving as CEO of Amylin from 2007 to 2012 until its acquisition by Bristol-Myers Squibb.
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...